SCHEMBL5067564

SCHEMBL5067564

CNCCN1CCC(n2nc(C(F)(F)F)cc2C(=O)N2CCc3ccccc3C2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.43
DRD3 P35462 3/20 0.43
LMNA P02545 2/20 0.42
USP2 O75604 1/20 0.42
KMT2A Q03164 1/20 0.42
SPR P35270 1/20 0.40
HPGD P15428 3/20 0.39
MAPT P10636 2/20 0.39
TSHR P16473 2/20 0.39
MAPK1 P28482 2/20 0.39
KDM4E B2RXH2 2/20 0.39
RAB9A P51151 2/20 0.39
HSD17B10 Q99714 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
TP53 P04637 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CARM1 Q86X55 3/20 0.39
PRMT6 Q96LA8 3/20 0.39
ALDH1A1 P00352 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5067622 0.95 CARM1 (0.41) DRD2DRD3LMNAUSP2CARM1
SCHEMBL5067621 0.83 CARM1 (0.41) DRD2CARM1PRMT6
SCHEMBL5069665 0.77 CARM1 (0.44) CARM1PRMT6
SCHEMBL5067039 0.76 CARM1 (0.44) DRD2CARM1PRMT6
SCHEMBL5066896 0.75 CARM1 (0.58) CARM1
SCHEMBL5069685 0.74 CARM1 (0.49) CARM1
SCHEMBL5064263 0.73 CARM1 (0.49) LMNAHPGDMAPTMAPK1KDM4E
SCHEMBL5069644 0.73 CARM1 (0.48) CARM1
SCHEMBL5066895 0.73 CARM1 (0.48) CARM1PRMT6
SCHEMBL5066866 0.71 CARM1 (0.43) HTTCARM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338437-B2 Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy METHYLGENE INC. (CA) 2012-12-25 US disclosed
US-20080280925-A1 Amines as Small Molecule Inhibitors METHYLGENE INC. 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280925-A1 Amines as Small Molecule Inhibitors CARM1, PRMT1, PRMT3 DRD2 3737/4885DRD3 3359/4885LMNA 3258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.